Clinical Trial Update: 18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System [Phase 2]

View source ↗

Summary

The Phase 2 trial evaluating the radiopharmaceutical 18F-mFBG for neural crest tumors has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma
• Paraganglioma
• Pheochromocytoma

Drugs mentioned

• [18F]-MFBG (18F-MFBG)

Snippet

Sponsor: Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) | Conditions: Neuroblastoma, Pheochromocytoma | Phase 2 | Status: WITHDRAWN